KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments (2016 - 2017)

Jazz Pharmaceuticals has reported Short-Term Debt repayments over the past 3 years, most recently at -$350.0 million for Q4 2017.

  • Quarterly results put Short-Term Debt repayments at -$350.0 million for Q4 2017, down 333.33% from a year ago — trailing twelve months through Sep 2018 was -$350.0 million (down 135.0% YoY), and the annual figure for FY2020 was $500.0 million, changed.
  • Short-Term Debt repayments for Q4 2017 was -$350.0 million at Jazz Pharmaceuticals, down from $500.0 million in the prior quarter.
  • Over the last five years, Short-Term Debt repayments for JAZZ hit a ceiling of $500.0 million in Q3 2017 and a floor of -$350.0 million in Q4 2017.
  • Median Short-Term Debt repayments over the past 3 years was $150.0 million (2016), compared with a mean of $121.7 million.
  • Biggest five-year swings in Short-Term Debt repayments: skyrocketed 87.5% in 2016 and later crashed 333.33% in 2017.
  • Jazz Pharmaceuticals' Short-Term Debt repayments stood at $80.0 million in 2015, then skyrocketed by 87.5% to $150.0 million in 2016, then tumbled by 333.33% to -$350.0 million in 2017.
  • The last three reported values for Short-Term Debt repayments were -$350.0 million (Q4 2017), $500.0 million (Q3 2017), and $200.0 million (Q2 2017) per Business Quant data.